Florence Curtis S, Zhou Chao, Luo Feijun, Xu Likang
National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA.
Med Care. 2016 Oct;54(10):901-6. doi: 10.1097/MLR.0000000000000625.
It is important to understand the magnitude and distribution of the economic burden of prescription opioid overdose, abuse, and dependence to inform clinical practice, research, and other decision makers. Decision makers choosing approaches to address this epidemic need cost information to evaluate the cost effectiveness of their choices.
To estimate the economic burden of prescription opioid overdose, abuse, and dependence from a societal perspective.
DESIGN, SETTING, AND PARTICIPANTS: Incidence of fatal prescription opioid overdose from the National Vital Statistics System, prevalence of abuse and dependence from the National Survey of Drug Use and Health. Fatal data are for the US population, nonfatal data are a nationally representative sample of the US civilian noninstitutionalized population ages 12 and older. Cost data are from various sources including health care claims data from the Truven Health MarketScan Research Databases, and cost of fatal cases from the WISQARS (Web-based Injury Statistics Query and Reporting System) cost module. Criminal justice costs were derived from the Justice Expenditure and Employment Extracts published by the Department of Justice. Estimates of lost productivity were based on a previously published study.
Calendar year 2013.
Monetized burden of fatal overdose and abuse and dependence of prescription opioids.
The total economic burden is estimated to be $78.5 billion. Over one third of this amount is due to increased health care and substance abuse treatment costs ($28.9 billion). Approximately one quarter of the cost is borne by the public sector in health care, substance abuse treatment, and criminal justice costs.
These estimates can assist decision makers in understanding the magnitude of adverse health outcomes associated with prescription opioid use such as overdose, abuse, and dependence.
了解处方阿片类药物过量、滥用及成瘾的经济负担的规模和分布,对于指导临床实践、研究及其他决策者而言至关重要。选择应对这一流行病方法的决策者需要成本信息,以评估其选择的成本效益。
从社会角度估算处方阿片类药物过量、滥用及成瘾的经济负担。
设计、背景和参与者:来自国家生命统计系统的致命处方阿片类药物过量发病率,来自国家药物使用和健康调查的滥用及成瘾患病率。致命数据针对美国人口,非致命数据是12岁及以上美国非机构化平民人口的全国代表性样本。成本数据来自各种来源,包括来自Truven Health MarketScan研究数据库的医疗保健索赔数据,以及来自WISQARS(基于网络的伤害统计查询和报告系统)成本模块的致命病例成本。刑事司法成本来自美国司法部公布的《司法支出和就业摘要》。生产力损失估计基于此前发表的一项研究。
2013年日历年。
致命过量及处方阿片类药物滥用和成瘾的货币化负担。
估计总经济负担为785亿美元。其中超过三分之一是由于医疗保健和药物滥用治疗成本增加(289亿美元)。约四分之一的成本由公共部门承担,包括医疗保健、药物滥用治疗和刑事司法成本。
这些估计数可帮助决策者了解与处方阿片类药物使用相关的不良健康后果的严重程度,如过量、滥用和成瘾。